20,761 Shares in GH Research PLC (NASDAQ:GHRS) Bought by Millennium Management LLC

Millennium Management LLC acquired a new stake in GH Research PLC (NASDAQ:GHRS - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 20,761 shares of the company's stock, valued at approximately $145,000.

Several other hedge funds also recently added to or reduced their stakes in GHRS. Lynx1 Capital Management LP grew its holdings in shares of GH Research by 15.8% during the fourth quarter. Lynx1 Capital Management LP now owns 4,858,994 shares of the company's stock worth $34,013,000 after buying an additional 663,100 shares in the last quarter. Diadema Partners LP acquired a new position in shares of GH Research in the fourth quarter worth $711,000. Northern Trust Corp lifted its stake in GH Research by 26.8% in the fourth quarter. Northern Trust Corp now owns 40,834 shares of the company's stock worth $286,000 after acquiring an additional 8,641 shares during the last quarter. BNP Paribas Financial Markets acquired a new position in shares of GH Research during the 4th quarter worth about $44,000. Finally, AdvisorShares Investments LLC raised its stake in GH Research by 15.4% during the 4th quarter. AdvisorShares Investments LLC now owns 36,011 shares of the company's stock worth $252,000 after acquiring an additional 4,806 shares in the last quarter. 56.90% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

GHRS has been the subject of several research analyst reports. Stifel Nicolaus increased their price objective on GH Research from $18.00 to $32.00 and gave the stock a "buy" rating in a research report on Thursday, February 27th. Royal Bank of Canada initiated coverage on shares of GH Research in a research report on Friday, March 7th. They issued an "outperform" rating and a $31.00 price objective for the company. HC Wainwright reaffirmed a "buy" rating and set a $40.00 target price on shares of GH Research in a research report on Friday, May 9th. Guggenheim dropped their price target on GH Research from $32.00 to $29.00 and set a "buy" rating on the stock in a research report on Friday, May 9th. Finally, Cantor Fitzgerald began coverage on GH Research in a report on Wednesday, June 4th. They set an "overweight" rating and a $25.00 price target on the stock. One research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company's stock. According to MarketBeat, GH Research presently has a consensus rating of "Moderate Buy" and an average price target of $32.00.

GH Research Stock Performance

GHRS traded down $0.07 during trading on Friday, reaching $12.76. 146,854 shares of the stock were exchanged, compared to its average volume of 187,241. GH Research PLC has a twelve month low of $6.00 and a twelve month high of $20.50. The stock has a market cap of $663.88 million, a P/E ratio of -16.15 and a beta of 0.97. The stock's 50 day moving average price is $10.66 and its two-hundred day moving average price is $10.35.

GH Research (NASDAQ:GHRS - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.61) by $0.42. Equities research analysts predict that GH Research PLC will post -0.8 earnings per share for the current fiscal year.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).